Edition:
United Kingdom

People: Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

2.38USD
9:00pm BST
Change (% chg)

$-0.04 (-1.65%)
Prev Close
$2.42
Open
$2.43
Day's High
$2.43
Day's Low
$2.38
Volume
11,530
Avg. Vol
24,690
52-wk High
$6.35
52-wk Low
$1.96

Rocklage, Scott 

Dr. Scott M. Rocklage, Ph.D. is no longer Chairman of the Board at the Company, effective June 2019. He has served as a member of our Board since 2013. Dr. Rocklage joined 5AM Ventures, a venture capital firm, in 2003 as a Venture Partner and became a Managing Partner in 2004. Prior to joining 5AM Ventures, Dr. Rocklage served as Chief Executive Officer and Chairman of the Board of Cubist Pharmaceuticals Inc., a publicly-traded pharmaceutical company, from 1994 to 2003 and as President and Chief Executive Officer of Nycomed Salutar, Inc., a diagnostic imaging company, from 1986 to 1989. Dr. Rocklage has also served in various research and development positions at Nycomed and Catalytica, Inc., a private pharmaceutical company. Dr. Rocklage currently serves as the chairman of the board of directors of Rennovia, Inc., a private bio-renewable chemical company, Kinestral Technologies, a private technology company, Aprea Therapeutics, a private biopharmaceutical company, and Expansion Therapeutics, a private biopharmaceutical company. Dr. Rocklage previously served on the board of directors of Achaogen, Inc., Epirus Biopharmaceuticals, Inc., Relypsa, Inc., and VBI Vaccines, Inc., all public biopharmaceutical companies, and Pulmatrix, Inc., a public biotechnology company. Dr. Rocklage holds a B.S. in chemistry from the University of California, Berkeley and a Ph.D. in chemistry from the Massachusetts Institute of Technology.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --